Advertisement

Topics

PellePharm Company Profile

16:18 EDT 18th March 2019 | BioPortfolio

Founded by world leaders in hedgehog signaling, PellePharm, a BridgeBio company, is committed to targeting rare genetic dermatological conditions, including Gorlin Syndrome and Basal Cell Carcinomas (BCCs), at the source. PellePharm is committed to improving the quality of life for those suffering from Gorlin Syndrome and BCCs by providing an easy-to-use topical solution that eliminates the need for regular, painful surgeries. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor.


News Articles [27 Associated News Articles listed on BioPortfolio]

Leo Pharma, PellePharm Launch $760M+ Rare Skin Disease Alliance

Leo Pharma will partner to develop and commercialize PellePharm’s Phase III-bound patidegib topical gel 2% for Gorlin syndrome, the companies said today, in a potentially $760 million-plus collabora...

PellePharm Inks $70M Deal with LEO Pharma for Skin Cancer Drug

PellePharm now has a partner to finance late-stage clinical tests of its experimental treatment for a rare skin cancer that has no FDA-approved drug treatment. Denmark-based LEO Pharma has agreed to p...

Leo Pharma partners with PellePharm in rare skin diseases; gains option to acquire

Leo Pharma AS and PellePharm Inc. have agreed to collaborate on the development and commercialization of therapeutics for rare skin diseases, including Gorlin syndrome, a rare genetic form of basal ce...

LEO Pharma, PellePharm form $760m rare skin disease collaboration

LEO Pharma research vice president Thorsten Thormann said: “We are very excited about the partnership with PellePharm, who are pioneers in Gorlin Syndrome and experts in rare skin The post LEO Phar...

PellePharm to Present at Piper Jaffray Healthcare Conference

PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, today announced that Sanuj K. Ravindran, M.D., chi...

Leo Lines Up PellePharm Buy In Rare Skin Cancer Deal

The Danish dermatology specialist could be hitting the acquisition trail again soon having taken an option to buy BridgeBio's PellePharm...   

PellePharm to Present at Cantor Fitzgerald Global Healthcare Conference

PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, today announced that Sanuj K. Ravindran, M.D., chi...

PellePharm’s Phase III Skin Disease Trial is Back on Track Following Agreement with LEO Pharma

Denmark-based LEO Pharma and California rare disease drugmaker PellePharm entered into a strategic collaboration worth $760 million to address unmet needs in multiple orphan skin diseases, such as Gor...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

PellePharm

Founded by world leaders in hedgehog signaling, PellePharm, a BridgeBio company, is committed to targeting rare genetic dermatological conditions, including Gorlin Syndrome and Ba...

More Information about "PellePharm" on BioPortfolio

We have published hundreds of PellePharm news stories on BioPortfolio along with dozens of PellePharm Clinical Trials and PubMed Articles about PellePharm for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PellePharm Companies in our database. You can also find out about relevant PellePharm Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record